Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 11/04/26
Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-OncologyPRNewsWire • 10/27/26
Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung CancerPRNewsWire • 09/23/26
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized DrugmakersZacks Investment Research • 09/01/26
Astellas enters voluntary agreement with U.S. government supporting affordable access to medicinesPRNewsWire • 08/31/26
Impax International Sustainable Economy Fund Q2 2026 Contributors And DetractorsSeeking Alpha • 08/13/26
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 06/05/26
Astellas Pharma Inc. (ALPMY) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/04/26
Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth CompanyPRNewsWire • 05/26/26
Astellas to Highlight New Findings for Geographic Atrophy at ARVO 2026 Annual MeetingPRNewsWire • 04/30/26
Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare TranscriptSeeking Alpha • 04/06/26
Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) BullishSeeking Alpha • 02/24/26
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate CancerPRNewsWire • 02/23/26
India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in USReuters • 02/10/26
Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26